LLY

1,074.85

+0.75%↑

JNJ

230.34

-1.8%↓

ABBV

212.12

-1.85%↓

UNH

380.23

-2.05%↓

AZN

187.05

-0.11%↓

LLY

1,074.85

+0.75%↑

JNJ

230.34

-1.8%↓

ABBV

212.12

-1.85%↓

UNH

380.23

-2.05%↓

AZN

187.05

-0.11%↓

LLY

1,074.85

+0.75%↑

JNJ

230.34

-1.8%↓

ABBV

212.12

-1.85%↓

UNH

380.23

-2.05%↓

AZN

187.05

-0.11%↓

LLY

1,074.85

+0.75%↑

JNJ

230.34

-1.8%↓

ABBV

212.12

-1.85%↓

UNH

380.23

-2.05%↓

AZN

187.05

-0.11%↓

LLY

1,074.85

+0.75%↑

JNJ

230.34

-1.8%↓

ABBV

212.12

-1.85%↓

UNH

380.23

-2.05%↓

AZN

187.05

-0.11%↓

Home・Listă Acțiuni・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Deschisă

SectorSănătate

21.26 2.31

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

20.65

Maxim

21.16

Indicatori cheie
By Trading Economics
Venit	-29M -11M
Vânzări	-24M 105M
EPS	-0.09
Marjă de profit	-10.717
Angajați	354
EBITDA	-31M -8.5M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+66.01% upside

Dividende
By Dow Jones
Următoarele câștiguri	5 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-433M 2.5B
Deschiderea anterioară	18.95
Închiderea anterioară	21.26

Sentimentul știrilor

By Acuity

46%

54%

142 / 345 Clasament în Healthcare

Arcutis Biotherapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

25 mai 2026, 08:24 UTC

Principalele dinamici ale pieței

Achiziții, Fuziuni, Preluări

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 mai 2026, 21:22 UTC

Câștiguri

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 mai 2026, 20:50 UTC

Market Talk

Câștiguri

Basic Materials Roundup: Market Talk

25 mai 2026, 16:20 UTC

Market Talk

Câștiguri

Basic Materials Roundup: Market Talk

25 mai 2026, 16:01 UTC

Market Talk

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 mai 2026, 14:43 UTC

Market Talk

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 mai 2026, 14:15 UTC

Market Talk

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 mai 2026, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25 mai 2026, 12:58 UTC

Market Talk

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 mai 2026, 12:56 UTC

Market Talk

Câștiguri

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 mai 2026, 12:48 UTC

Market Talk

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 mai 2026, 12:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25 mai 2026, 12:34 UTC

Market Talk

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 mai 2026, 12:10 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Delivery Hero's Assets Look Strategic -- Market Talk

25 mai 2026, 11:00 UTC

Market Talk

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 mai 2026, 10:19 UTC

Market Talk

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 mai 2026, 10:05 UTC

Câștiguri

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 mai 2026, 10:04 UTC

Câștiguri

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 mai 2026, 10:03 UTC

Câștiguri

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 mai 2026, 10:02 UTC

Câștiguri

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 mai 2026, 10:01 UTC

Câștiguri

Tenaga Nasional 1Q Net Up 3.7% on Year

25 mai 2026, 10:00 UTC

Câștiguri

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 mai 2026, 09:56 UTC

Câștiguri

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 mai 2026, 09:56 UTC

Câștiguri

Tenaga Nasional 1Q EPS MYR0.1883

25 mai 2026, 09:56 UTC

Câștiguri

Tenaga Nasional 1Q Rev MYR17.1B

25 mai 2026, 09:56 UTC

Câștiguri

Tenaga Nasional 1Q Net MYR1.1B

25 mai 2026, 09:38 UTC

Market Talk

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 mai 2026, 09:33 UTC

Market Talk

Global Equities Roundup: Market Talk

25 mai 2026, 09:33 UTC

Market Talk

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 mai 2026, 08:55 UTC

Market Talk

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Comparație

Modificare preț

Arcutis Biotherapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

66.01% sus

Prognoză pe 12 luni

Medie 34.63 USD 66.01%

Maxim 36 USD

Minim 33 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruArcutis Biotherapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

8 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 8 analiști care au acordat evaluări ale acțiunilor Arcutis Biotherapeutics Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

142 / 345 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.